Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160167 · ClinicalTrials.gov registry record
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 4,204
- Enrollment target
NCT06160167: Completed study, sponsored by Bristol-Myers Squibb.
NCT06160167 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 4,204 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06160167 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 4,204 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.
Primary Outcome
Each qualified patient must have at least 6 months of medical data recorded in the Flatiron database before the index date (pre-index period) and 6 months of available data on and after the index date (follow-up period).
Interventions
- DRUG IMiD treatment
- DRUG No IMiD treatment
- DRUG Systemic therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,204 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2024-08-01 |
What the finished NCT06160167 record still lists
NCT06160167 is an observational study that tracks outcomes without assigning an intervention. Its 4,204 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which IMiD treatment is the first listed.
NCT06160167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06160167 about?
NCT06160167 is a clinical study titled "Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs". The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical recor...
What is the current status of trial NCT06160167?
This trial is currently completed. The enrollment target is 4,204 participants. The study started on 2023-10-01. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT06160167?
The interventions under investigation include: IMiD treatment (DRUG), No IMiD treatment (DRUG), Systemic therapy (DRUG).
Who is sponsoring clinical trial NCT06160167?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- NCT07209098 · 4,200 participants
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI